Log in
/
Register
Home
Overview
Upload / Manage Data
Browse / Search Studies
Analyze Studies
Tutorials
FAQ
Data Repository
Overview
Upload / Manage Studies
Browse / Search Studies
Analyze Studies
Data Sharing Policy
Tutorials
FAQ
Databases
Overview
Metabolite Database
Human Metabolome Gene/Protein Database (MGP)
RefMet: Reference List of Metabolite Names
External Metabolomics Databases (Links)
Protocols
Overview
General Protocols
Study-specific Protocols
Tools
Overview
Load and analyze your own dataset
Analyze Studies
MS Searches
Structure drawing
REST Service
External Tools (Links)
About
Overview
Publishing Partners
How to Cite
How to Link
Terms of Use
Personnel
Contact
Sitemap
Search
Keyword Search
Advanced Searches
Clustering data with hclust algorithm for (Study ST000683)
(Analysis AN001052)
Metabolite
Structure
F1
F2
PA 34:0; [M-H]-@6.82
ME190074
1.00
NA
PE 36:1; [M-H]-@7.46
ME190138
0.61
1.39
PG 34:3; [M-H]-@4.64
ME190180
0.63
1.37
PG 38:4; [M-H]-@6.09
ME190190
0.62
1.38
plasmenyl-PE 34:1; [M-H]-@7.18
ME190233
0.62
1.38
PE 42:10; [M-H]-@5.81
ME190171
0.70
1.30
PG 36:2; [M-H]-@6.03
ME190182
0.71
1.29
PG 36:4; [M-H]-@5.46
ME190185
0.71
1.29
N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45
ME190072
0.66
1.34
PG 34:2; [M-H]-@5.24
ME190179
0.69
1.31
plasmenyl-PE 34:2; [M-H]-@6.76
ME190234
0.68
1.32
PG 36:4; [M-H]-@5.00
ME190184
0.68
1.32
PG 38:3; [M-H]-@5.81
ME190188
0.68
1.32
PG 40:7; [M-H]-@4.98
ME190196
0.75
1.25
plasmenyl-PE 42:4; [M-H]-@8.17
ME190249
0.74
1.26
PG 38:2; [M-H]-@6.19
ME190187
0.74
1.26
FFA(20:1)
ME190057
0.74
1.26
FFA(24:3)
ME190067
0.74
1.26
lysoPE 18:1; [M-H]-@1.86
ME190222
0.73
1.27
PG 36:3; [M-H]-@5.36
ME190183
0.73
1.27
PG 38:7; [M-H]-@4.41
ME190193
0.78
1.22
PC 36:1; [M-Ac-H]-@7.35
ME190090
0.78
1.22
PC 38:2; [M-Ac-H]-@7.53
ME190099
0.78
1.22
FFA(24:2)
ME190066
0.76
1.24
PG 38:4; [M-H]-@5.43
ME190189
0.76
1.24
plasmenyl-PE 38:6; [M-H]-@6.57
ME190245
0.77
1.23
PG 44:11; [M-H]-@4.88
ME190203
0.77
1.23
PC 38:3; [M-Ac-H]-@7.14
ME190100
0.77
1.23
PE 42:6; [M-H]-@7.49
ME190172
0.77
1.23
PC 38:7; [M-Ac-H]-@5.62
ME190104
1.04
0.96
plasmenyl-PE 38:1; [M-H]-@8.28
ME190240
1.05
0.95
PE 36:4; [M-H]-@6.21
ME190141
1.05
0.95
PC 38:4; [M-Ac-H]-@6.77
ME190101
1.05
0.95
PE 35:4; [M-H]-@6.05
ME190136
1.05
0.95
plasmenyl-PE 42:5; [M-H]-@7.90
ME190250
1.06
0.94
PE 34:1; [M-H]-@6.87
ME190128
1.06
0.94
PC 40:3; [M-Ac-H]-@7.61
ME190109
1.06
0.94
PC 37:3; [M-Ac-H]-@6.77
ME190097
1.06
0.94
PC 38:5; [M-Ac-H]-@6.37
ME190102
1.06
0.94
PG 42:9; [M-H]-@4.87
ME190201
1.07
0.93
PG 42:11; [M-H]-@4.20
ME190200
1.07
0.93
PE 38:4; [M-H]-@6.89
ME190153
1.07
0.93
PE 37:6; [M-H]-@5.97
ME190148
1.07
0.93
PC 40:6; [M-Ac-H]-@6.69
ME190111
1.07
0.93
PE 35:3; [M-H]-@6.23
ME190135
1.07
0.93
PE 38:1; [M-H]-@7.97
ME190150
1.09
0.91
PE 38:3; [M-H]-@7.26
ME190152
1.08
0.92
PC 40:8; [M-Ac-H]-@5.81
ME190113
1.08
0.92
PE 34:2; [M-H]-@6.41
ME190129
1.08
0.92
PS 38:6; [M-H]-@5.22
ME190215
1.00
1.00
PS 38:4; [M-H]-@6.01
ME190213
1.00
1.00
PE 40:7; [M-H]-@6.39
ME190166
1.00
1.00
PE 34:3; [M-H]-@5.97
ME190130
1.00
1.00
PC 34:3; [M-Ac-H]-@5.84
ME190085
1.00
1.00
PC 35:2; [M-Ac-H]-@6.62
ME190088
1.00
1.00
PG 44:10; [M-H]-@5.11
ME190202
1.01
0.99
PE 40:4; [M-H]-@7.50
ME190163
1.01
0.99
PE 38:6; [M-H]-@6.11
ME190155
1.01
0.99
PE 38:1; [M-H]-@7.37
ME190149
1.01
0.99
PC 40:9; [M-Ac-H]-@5.45
ME190114
1.01
0.99
PE 32:1; [M-H]-@6.24
ME190123
1.01
0.99
PE 36:3; [M-H]-@6.56
ME190140
1.02
0.98
PE 35:0; [M-H]-@7.58
ME190132
1.02
0.98
PE 33:2; [M-H]-@6.05
ME190126
1.02
0.98
PE 32:2; [M-H]-@5.77
ME190124
1.02
0.98
PC 36:4; [M-Ac-H]-@6.16
ME190093
1.02
0.98
PC 36:5; [M-Ac-H]-@5.67
ME190094
1.02
0.98
PS 40:6; [M-H]-@5.92
ME190217
1.03
0.97
PG 42:10; [M-H]-@4.53
ME190199
1.03
0.97
PE 39:6; [M-H]-@6.56
ME190160
1.03
0.97
PE 40:6; [M-H]-@6.76
ME190165
1.03
0.97
PC 40:7; [M-Ac-H]-@6.25
ME190112
0.99
1.01
PC 37:2; [M-Ac-H]-@7.26
ME190096
0.99
1.01
IS PC 34:0;[M-Ac-H]-
ME190068
0.99
1.01
lysoPE 17:0; [M-H]-@2.05
ME190220
0.99
1.01
PS 36:4; [M-H]-@5.33
ME190211
0.98
1.02
plasmenyl-PE 40:4; [M-H]-@7.73
ME190246
0.98
1.02
PG 38:6; [M-H]-@4.74
ME190192
0.98
1.02
PC 42:10; [M-Ac-H]-@5.75
ME190115
0.98
1.02
PC 32:0; [M-Ac-H]-@6.65
ME190077
0.98
1.02
PC 34:0; [M-Ac-H]-@7.28
ME190082
0.98
1.02
PE 39:7; [M-H]-@6.08
ME190161
0.95
1.05
PC 32:1; [M-Ac-H]-@6.11
ME190078
0.95
1.05
PE 38:5; [M-H]-@6.48
ME190154
0.95
1.05
PE 42:8; [M-H]-@6.55
ME190174
0.96
1.04
PE 32:0; [M-H]-@6.77
ME190122
0.96
1.04
FFA(16:0)
ME190052
0.96
1.04
PC 42:11; [M-Ac-H]-@5.31
ME190116
0.96
1.04
PG 40:5; [M-H]-@5.64
ME190194
0.97
1.03
PE 38:7; [M-H]-@5.71
ME190157
0.97
1.03
PC 38:6; [M-Ac-H]-@6.01
ME190103
0.97
1.03
PC 33:1; [M-Ac-H]-@6.48
ME190080
0.97
1.03
PC 36:6; [M-Ac-H]-@5.46
ME190095
0.97
1.03
PS 40:4; [M-H]-@6.44
ME190216
0.92
1.08
plasmenyl-PE 40:6; [M-H]-@7.20
ME190248
0.92
1.08
plasmenyl-PE 38:5; [M-H]-@6.75
ME190244
0.92
1.08
FFA(20:0)
ME190056
0.92
1.08
PG 40:8; [M-H]-@4.58
ME190197
0.92
1.08
plasmenyl-PE 36:5; [M-H]-@6.31
ME190239
0.93
1.07
plasmenyl-PE 36:1; [M-H]-@7.76
ME190235
0.93
1.07
PG 36:1; [M-H]-@6.45
ME190181
0.93
1.07
PG 34:1; [M-H]-@5.85
ME190178
0.93
1.07
PE 40:7; [M-H]-@7.56
ME190167
0.93
1.07
PE 35:1; [M-H]-@7.14
ME190133
0.93
1.07
PC 32:2; [M-Ac-H]-@5.65
ME190079
0.93
1.07
lysoPE 20:4; [M-H]-@1.28
ME190229
0.93
1.07
lysoPE 20:1; [M-H]-@2.66
ME190226
0.93
1.07
CerP 34:1; [M-H]-@5.87
ME190051
0.93
1.07
lysoPE 16:1; [M-H]-@1.22
ME190219
0.93
1.07
plasmenyl-PE 36:2; [M-H]-@7.34
ME190236
0.94
1.06
PE 36:0; [M-H]-@7.87
ME190137
0.94
1.06
FFA(18:0)
ME190053
0.94
1.06
PC 40:4; [M-Ac-H]-@7.49
ME190110
0.94
1.06
plasmenyl-PE 40:5; [M-H]-@7.46
ME190247
0.89
1.11
PC 36:2; [M-Ac-H]-@6.90
ME190091
0.89
1.11
PC 36:3; [M-Ac-H]-@6.42
ME190092
0.89
1.11
plasmenyl-PE 38:4; [M-H]-@7.23
ME190243
0.91
1.09
PG 40:9; [M-H]-@4.19
ME190198
0.91
1.09
PE 36:4; [M-H]-@7.57
ME190142
0.91
1.09
PC 37:4; [M-Ac-H]-@6.55
ME190098
0.91
1.09
PC 34:2; [M-Ac-H]-@6.23
ME190084
0.91
1.09
lysoPE 20:3; [M-H]-@1.64
ME190228
0.91
1.09
FFA(18:1)
ME190054
0.91
1.09
FFA(22:0)
ME190060
0.91
1.09
PE 39:3; [M-H]-@7.49
ME190158
0.90
1.10
PE 38:2; [M-H]-@7.53
ME190151
0.90
1.10
PE 36:2; [M-H]-@7.01
ME190139
0.90
1.10
PC 42:5; [M-Ac-H]-@7.56
ME190117
0.90
1.10
FFA(22:1)
ME190061
0.90
1.10
FFA(18:2)
ME190055
0.90
1.10
FFA(20:4) Arachidonic acid
ME190059
0.90
1.10
FFA(24:0)
ME190064
0.82
1.18
lysoPE 22:4; [M-H]-@1.86
ME190230
0.82
1.18
PE 34:0; [M-H]-@7.29
ME190127
0.81
1.19
PC 44:12; [M-Ac-H]-@5.64
ME190121
0.81
1.19
PC 30:1; [M-Ac-H]-@5.49
ME190076
0.81
1.19
PC 42:7; [M-Ac-H]-@6.85
ME190119
0.81
1.19
PE 40:8; [M-H]-@5.99
ME190168
0.79
1.21
PS 38:5; [M-H]-@5.45
ME190214
0.80
1.20
PG 38:5; [M-H]-@5.10
ME190191
0.80
1.20
PC 33:2; [M-Ac-H]-@6.04
ME190081
0.80
1.20
PA 34:2; [M-H]-@6.30
ME190075
0.80
1.20
lysoPE 22:6; [M-H]-@1.24
ME190232
0.80
1.20
FFA(22:3)
ME190063
0.80
1.20
lysoPE 22:5; [M-H]-@1.58
ME190231
0.80
1.20
PE 36:5; [M-H]-@5.89
ME190143
0.83
1.17
PC 42:8; [M-Ac-H]-@6.41
ME190120
0.83
1.17
N-(hexadecanoyl)-sphing-4-enine; [M-H]-@6.83
ME190071
0.83
1.17
lysoPE 18:2; [M-H]-@1.32
ME190223
0.83
1.17
FFA(20:2)
ME190058
0.83
1.17
lysoPE 18:0; [M-H]-@2.49
ME190221
0.83
1.17
plasmenyl-PE 38:3; [M-H]-@7.56
ME190242
0.84
1.16
PG 40:6; [M-H]-@5.44
ME190195
0.84
1.16
lysoPE 19:0; [M-H]-@3.04
ME190224
0.84
1.16
PG 36:5; [M-H]-@4.52
ME190186
0.84
1.16
N-(15Z-tetracosenoyl)-sphing-4-enine; [M-H]-@8.47
ME190069
0.88
1.12
PG 34:0; [M-H]-@6.34
ME190177
0.88
1.12
plasmenyl-PE 36:4; [M-H]-@6.71
ME190238
0.87
1.13
PE 42:7; [M-H]-@6.99
ME190173
0.87
1.13
PE 41:4; [M-H]-@7.62
ME190170
0.87
1.13
PC 35:1; [M-Ac-H]-@7.09
ME190087
0.87
1.13
PE 38:6; [M-H]-@7.64
ME190156
0.87
1.13
N-(eicosanoyl)-sphing-4-enine; [M-H]-@7.96
ME190070
0.85
1.15
lysoPE 20:2; [M-H]-@2.08
ME190227
0.85
1.15
lysoPE 16:0; [M-H]-@1.69
ME190218
0.85
1.15
FFA(22:2)
ME190062
0.85
1.15
FFA(24:1)
ME190065
0.85
1.15
PS 37:4; [M-H]-@5.64
ME190212
0.86
1.14
N-(tetracosanoyl)-sphing-4-enine; [M-H]-@8.92
ME190073
0.86
1.14
PC 34:1; [M-Ac-H]-@6.71
ME190083
0.86
1.14
PC 34:4; [M-Ac-H]-@5.57
ME190086
1.11
0.89
PG 44:12; [M-H]-@4.44
ME190204
1.13
0.87
plasmenyl-PE 42:6; [M-H]-@7.74
ME190251
1.12
0.88
plasmenyl-PE 36:3; [M-H]-@6.96
ME190237
1.12
0.88
PG 33:0; [M-H]-@6.06
ME190176
1.12
0.88
PE 37:5; [M-H]-@6.17
ME190147
1.12
0.88
PC 39:4; [M-Ac-H]-@7.17
ME190105
1.12
0.88
PE 37:2; [M-H]-@7.29
ME190145
1.12
0.88
PE 35:2; [M-H]-@6.71
ME190134
1.17
0.83
PI 36:4; [M-H]-@5.24
ME190207
1.18
0.82
PC 39:5; [M-Ac-H]-@6.71
ME190106
1.18
0.82
PC 42:6; [M-Ac-H]-@7.42
ME190118
1.18
0.82
PE 40:9; [M-H]-@5.54
ME190169
1.16
0.84
PE 40:2; [M-H]-@8.00
ME190162
1.14
0.86
plasmenyl-PE 38:2; [M-H]-@7.89
ME190241
1.15
0.85
PC 39:6; [M-Ac-H]-@6.43
ME190107
1.15
0.85
PE 34:4; [M-H]-@5.71
ME190131
1.15
0.85
PI 36:2; [M-H]-@5.94
ME190206
1.28
0.72
PE 33:1; [M-H]-@6.58
ME190125
1.23
0.77
PI 38:4; [M-H]-@5.87
ME190209
1.23
0.77
CL 76:10; [M-2H](2-)@9.07
ME190050
1.20
0.80
PI 38:5; [M-H]-@5.40
ME190210
1.21
0.79
PE 39:4; [M-H]-@7.22
ME190159
1.21
0.79
PC 39:7; [M-Ac-H]-@5.99
ME190108
1.21
0.79
PE 37:4; [M-H]-@6.72
ME190146
1.21
0.79
CL 72:7; [M-2H](2-)@9.09
ME190046
1.42
0.58
CL 72:8; [M-2H](2-)@8.92
ME190047
1.39
0.61
CL 74:8; [M-2H](2-)@9.18
ME190048
1.40
0.60
lysoPE 20:0; [M-H]-@3.48
ME190225
1.32
0.68
PI 38:3; [M-H]-@6.09
ME190208
1.34
0.66
PE 36:6; [M-H]-@5.53
ME190144
1.36
0.64
CL 72:6; [M-2H](2-)@9.30
ME190045
1.35
0.65
PG 44:9; [M-H]-@5.47
ME190205
1.35
0.65
CL 74:9; [M-2H](2-)@9.03
ME190049
1.57
0.43
PC 35:3; [M-Ac-H]-@6.11
ME190089
1.48
0.52
PE 40:5; [M-H]-@7.21
ME190164
NA
1.00
PG 32:1; [M-H]-@5.29
ME190175
0.27
1.73
Factors:
F1
Type:knockout
F2
Type:wild type
Data matrix
UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
Terms of use
Site map
Contact
NMDR Personnel